Der Maus Monoklonal Anti-RSV Fusion Protein Antikörper wurde für ELISA, IF, WB, FACS, IEM und IP validiert. Er ist geeignet, RSV Fusion Protein in Proben von Respiratory Syncytial Virus (RSV) zu detektieren. Es sind 3+ Publikationen verfügbar.
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1.0 mg/mL
Adams, Bonzel, Kovacevic, Mayatepek, Hoehn, Vogel: "Palivizumab-resistant human respiratory syncytial virus infection in infancy." in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 51, Issue 2, pp. 185-8, (2010) (PubMed).
Eckardt-Michel, Lorek, Baxmann, Grunwald, Keil, Zimmer: "The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis." in: Journal of virology, Vol. 82, Issue 7, pp. 3236-49, (2008) (PubMed).
Mason, Lawetz, Gaudette, Dô, Scouten, Lagacé, Simoneau, Liuzzi: "Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor." in: Nucleic acids research, Vol. 32, Issue 16, pp. 4758-67, (2004) (PubMed).
Target
RSV Fusion Protein (RSV F)
(Respiratory Syncytial Virus Fusion Protein (RSV F))